

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 97/18212

(51) International Patent Classification 6:

C07D 473/34, 473/30, 473/38, 473/00,  
471/04, A61K 31/52

A1

(11) International Publication Number:

22 May 1997 (22.05.97)

(43) International Publication Date:

(21) International Application Number:

PCT/EP06/04460

(22) International Filing Date:

14 October 1996 (14.10.96)

(30) Priority Data:  
9523242.7  
9524131.1

14 November 1995 (14.11.95) GB  
24 November 1995 (24.11.95) GB

(71) Applicant (for all designated States except US): PHARMACIA  
& UPJOHN S.P.A. (IT/IT); Via Robert Koch, 1.2, I-20152  
Milan (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BUZZETTI, Franco  
(IT/IT); Via della Gallarate, 4, I-20052 Monza (IT).  
BRASCA, Maria, Gabriella (IT/IT); Via Dante Alighieri,  
15, I-20090 Cusago (IT). LONGO, Antonio (IT/IT);  
Via Nicola Antonio Porpora, 160, I-20131 Milan (IT).  
BALLINARI, Dario (IT/IT); Via C. Jannozzi, 8, I-20097  
San Donato Milanese (IT).

(81) Designated States: AU, BG, BR, BY, CA, CN, CZ, EE, HU,  
IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RU, SG, SI,  
TR, UA, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD,  
RU, TJ, TM). European patent (AT, BE, CH, DE, DK, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published


With international search report.

5965863

(54) Title: ARYL AND HETEROARYL PURINE COMPOUNDS

(57) Abstract

Novel bicyclic condensed pyrimidine compounds having general formula (I) wherein X is  $-\text{CH}_2-$ ,  $-\text{NH}-(\text{CH}_2)_n-$ ,  $-\text{O}-(\text{CH}_2)_n-$  or  $-\text{S}-(\text{CH}_2)_n-$  in which n is zero or 1; A is a 4,5-fused imidazole ring N-substituted by  $\text{R}_3$  which is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl or benzyl, or A is a 2,3-fused pyridine ring C-substituted by  $\text{R}_4$  which is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen or  $\text{NR}_5\text{R}_6$  in which each of  $\text{R}_5$  and  $\text{R}_6$  independently is H or C<sub>1</sub>-C<sub>4</sub> alkyl; B is a bicyclic ring chosen from tetralin, indane and 2-oxindole; each of  $\text{R}_1$  and  $\text{R}_2$ , independently, is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, halogen, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> alkoxycarbonyl, nitro, cyano or  $\text{CF}_3$ ; and the pharmaceutically acceptable salts thereof; and wherein, when at the same time, A is pyridine and B is a tetralin ring,  $\text{R}_4$  is H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy or halogen and X is as defined above, then each of  $\text{R}_1$  and  $\text{R}_2$  is other than H; and wherein, when at the same time, A is imidazole, X is  $-\text{NH}-(\text{CH}_2)_n-$  as defined above, and B is an indan ring unsubstituted or substituted by one or more of halogen, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy and nitro, then  $\text{R}_3$  is other than C<sub>1</sub>-C<sub>4</sub> alkyl or benzyl, are provided.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NI	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SW	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TC	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam


ARYL AND HETEROARYL PURINE COMPOUNDS

The present invention relates to new bicyclic condensed pyrimidine compounds, to a process for their preparation, to  
5 pharmaceutical compositions containing them and to their use as therapeutic agents, in particular as tyrosine kinase inhibitors.

EP-A-0414386 discloses 4-substituted pyrido[2,3-d]pyrimidine compounds which are plant fungicides, miticides and  
10 insecticides.

WO 90/09178 discloses 6,9-disubstituted purine compounds useful in adenosine-mediated lipolysis, cardiovascular diseases and broncodilatation.

15 The present invention provides novel bicyclic condensed pyrimidine compounds having the following general formula (I)



wherein

X is  $-\text{CH}_2-$ ,  $-\text{NH}-(\text{CH}_2)_n-$ ,  $-\text{O}-(\text{CH}_2)_n-$  or  $-\text{S}-(\text{CH}_2)_n-$  in which  
20 n is zero or 1 ;

A is a 4,5-fused imidazole ring N-substituted by  $\text{R}_3$  which is hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl or benzyl, or A is a 2,3-fused pyridine ring C-substituted by  $\text{R}_4$  which is hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl,  $\text{C}_1$ - $\text{C}_4$  alkoxy, halogen or  $\text{NR}_5\text{R}_6$  in which each of  $\text{R}_5$  and  $\text{R}_6$   
25 independently is H or  $\text{C}_1$ - $\text{C}_4$  alkyl;

B is a bicyclic ring chosen from tetralin, indane and 2-oxindole;

each of  $R_1$  and  $R_2$ , independently, is hydrogen,  $C_1$ - $C_4$  alkyl, halogen, hydroxy,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkoxy carbonyl, nitro, cyano or  $CF_3$ ;

and the pharmaceutically acceptable salts thereof; and  
5 wherein, when at the same time, A is pyridine and B is a tetralin ring,  $R_4$  is H,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy or halogen and X is as defined above, then each of  $R_1$  and  $R_2$  is other than H; and wherein, when at the same time, A is imidazole, X is  $-NH-(CH_2)_n-$  as defined above, and B is an indan ring  
10 unsubstituted or substituted by one or more of halogen, hydroxy,  $C_1$ - $C_4$  alkoxy and nitro, then  $R_3$  is other than  $C_1$ - $C_4$  alkyl or benzyl.

The X bridge may be located on either of the ring B moieties, preferably it is located on the benzene ring.

15 The  $R_3$  substituent is only located on the imidazole ring on a N-ring atom.

The  $R_4$  substituent is only located on the pyridine ring, preferably it is attached at the  $\alpha$ -position.

The  $R_1$  and  $R_2$  substituents in tetralin and indan may be on  
20 either of the ring moieties, preferably they are attached to the benzene moiety. In 2-oxindole the  $R_1$  and  $R_2$  substituents are preferably located on the benzene moiety. Thus the  $R_1$  and  $R_2$  substituents are preferably attached to the benzene moiety when B is tetralin, indan or 2-oxindole.

25 The invention includes within its scope all the possible isomers, stereoisomers and their mixtures, and the metabolites and the metabolic precursors or bio-precursors (otherwise known as prodrugs) of the compounds of formula (I).

30 The X bridge is preferably linked to position 1 or 2 when B

is tetralin and to position 5 when B is indane or 2-oxindole. Of course only one of the X, R<sub>1</sub> and R<sub>2</sub> substituents can be linked to the same position in ring B.

An alkyl group or an alkyl moiety in a alkoxy group may be  
5 branched or straight alkyl chains.

A C<sub>1</sub>-C<sub>4</sub> alkyl group is preferably a C<sub>1</sub>-C<sub>2</sub> alkyl, that is ethyl or methyl.

A C<sub>1</sub>-C<sub>4</sub> alkoxy group is preferably a methoxy or ethoxy group.

A halogen atom is for example fluoro, chloro, bromo or iodio,  
10 in particular bromo or fluoro.

It is understood that when A is a 4,5-fused imidazole moiety then a purine ring is formed and when A is a 2,3-fused pyridine moiety then a pyrido[2,3-d]pyrimidine ring is formed.

15 The term tetralin is meant to refer to 5,6,7,8-tetrahydronaphthalene. In term X when X is -NHCH<sub>2</sub>-, -OCH<sub>2</sub>- or -SCH<sub>2</sub>- it is understood that the linkage with the pyrimidine ring occurs through the N, O or S atom.

Pharmaceutically acceptable salts of the compounds of the  
20 invention include acid addition salts with inorganic acids, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric and phosphoric acid or organic acids, e.g. acetic, trifluoroacetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic  
25 and salicylic acid.

As stated above, the present invention also includes within its scope pharmaceutically acceptable bio-precursors (otherwise known as prodrugs of the compounds of formula (I)), i.e. compounds which have different formula to formula  
30 (I) above but which, nevertheless, upon administration to a human being are converted directly or indirectly in vivo into a compound of formula (I).

Preferred compounds of the invention are the compounds of formula (I), wherein X, A and B are as defined above; R<sub>1</sub> is hydrogen or halogen, R<sub>4</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkoxy, and R<sub>2</sub> and R<sub>3</sub> are H; and the pharmaceutically acceptable salts thereof.

Examples of preferred specific compounds of formula (I) are the following compounds:

- 4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;
- 10 7-methoxy-4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylmethylamino)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethylamino)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-yloxy)-pyrido[2,3-d]pyrimidine;
- 15 7-methoxy-4-(2-oxindol-5-yloxy)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;
- 20 4-(2-oxindol-5-ylmethylthio)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethylthio)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;
- 25 4-(5-indanylamino)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(5-indanylamino)-pyrido[2,3-d]pyrimidine;
- 4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine;
- 4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;
- 30 7-methoxy-4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;
- 4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;


- 7-methoxy-4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;  
5 7-methoxy-4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;  
N<sup>6</sup>-(1-tetralyl) adenine;  
N<sup>6</sup>-(3-bromo-1-tetralyl) adenine;  
10 N<sup>6</sup>-(5-indanyl) adenine;  
N<sup>6</sup>-(7-bromo-5-indanyl) adenine;  
N<sup>6</sup>-(2-oxindol-5-yl) adenine;  
N<sup>6</sup>-(1-tetralylmethyl) adenine;  
N<sup>6</sup>-(5-indanylmethyl) adenine;  
15 N<sup>6</sup>-(2-oxindol-5-ylmethyl) adenine;  
6-(1-tetralyloxy)-purine;  
6-(3-bromo-1-tetralyloxy)-purine;  
6-(5-indanyloxy)-purine;  
6-(7-bromo-5-indanyloxy)-purine;  
20 6-(2-oxindol-5-yloxy)-purine;  
6-(1-tetralylthio) purine;  
6-(3-bromo-1-tetralylthio)-purine;  
6-(5-indanylthio)-purine;  
6-(7-bromo-5-indanylthio)-purine;  
25 6-(2-oxoindol-5-ylthio)-purine;  
6-(1-tetralylmethyl)-purine;  
6-(3-bromo-1-tetralylmethyl)-purine;  
6-(5-indanylmethyl)-purine;  
6-(7-bromo-5-indanylmethyl)-purine;  
30 6-(2-oxindol-5-ylmethyl)-purine;  
6-(1-tetralylmethoxy)-purine;

- 6-(5-indanylmethoxy)-purine;  
 6-(2-oxindol-5-ylmethoxy)-purine;  
 6-(1-tetralylmethylthio)-purine;  
 6-(5-indanylmethylthio)-purine; and  
 5 6-(2-oxindol-5-ylmethylthio)-purine;  
 either as single isomers or as a mixture thereof and the  
 pharmaceutically acceptable salts thereof.

An object of the present invention is also to provide a  
 10 bicyclic condensed pyrimidine compound of formula (I), as  
 defined above, or a pharmaceutically acceptable salt thereof,  
 for use as an active therapeutic substance, in particular as  
 tyrosine kinase inhibitor.

A further object of the invention are pharmaceutical  
 15 compositions comprising a compound of formula (I), as defined  
 above, or a pharmaceutically salt thereof, as an active  
 principle, and a pharmaceutically acceptable excipient (which  
 can be a carrier and/or diluent).

20 A further object of the present invention is a bicyclic  
 condensed pyrimidine compound of formula (IA)



wherein

X is  $-\text{CH}_2-$ ,  $-\text{NH}-(\text{CH}_2)_n-$ ,  $-\text{O}-(\text{CH}_2)_n-$  or  $-\text{S}-(\text{CH}_2)_n-$  in which  
 25 n is zero or 1 ;

A is a 2,3-fused pyridine ring C-substituted by  $\text{R}_4$  which is  
 hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl,  $\text{C}_1$ - $\text{C}_4$  alkoxy, halogen or  $\text{NR}_5\text{R}_6$  in



which each of  $R_5$  and  $R_6$  independently is H or  $C_1$ - $C_4$  alkyl;

B is a bicyclic ring chosen from tetralin, indane and 2-oxindole;

each of  $R_1$  and  $R_2$ , independently, is hydrogen,  $C_1$ - $C_4$  alkyl, halogen, hydroxy,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkoxycarbonyl, nitro, cyano or  $CF_3$ ;

or a pharmaceutically acceptable salts thereof for use as an active therapeutic substance, in particular as tyrosine kinase inhibitor.

10

Examples of preferred specific compounds of formula (IA) are the following compounds:

- 4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;
- 15 4-(2-oxindol-5-ylmethylamino)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethylamino)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-yloxy)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-yloxy)-pyrido[2,3-d]pyrimidine;
- 20 4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylthio) pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylmethylthio)-pyrido[2,3-d]pyrimidine;
- 25 7-methoxy-4-(2-oxindol-5-ylmethylthio)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;
- 4-(5-indanylamino)-pyrido[2,3-d]pyrimidine;
- 30 7-methoxy-4-(5-indanylamino)-pyrido[2,3-d]pyrimidine;
- 4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine;

- 7-methoxy-4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine;  
4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;  
5 7-methoxy-4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;  
10 4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;  
4-(1-tetrahylamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetrahylamino)-pyrido[2,3-d]pyrimidine;  
4-(1-tetrahylmethylamino)-pyrido[2,3-d]pyrimidine;  
15 7-methoxy-4-(1-tetrahylmethylamino)-pyrido[2,3-d]pyrimidine;  
4-(1-tetrahyloxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetrahyloxy)-pyrido[2,3-d]pyrimidine;  
4-(1-tetrahylmethoxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetrahylmethoxy)-pyrido[2,3-d]pyrimidine;  
20 4-(1-tetrahylythio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetrahylythio)-pyrido[2,3-d]pyrimidine;  
4-(1-tetrahylmethylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetrahylmethylthio)-pyrido[2,3-d]pyrimidine;  
4-(1-tetrahylmethyl)-pyrido[2,3-d]pyrimidine; and  
25 7-methoxy-4-(1-tetrahylmethyl)-pyrido[2,3-d]pyrimidine;  
either as single isomers or as a mixture thereof and the  
pharmaceutically acceptable salts thereof.

A further object of the invention are pharmaceutical  
30 compositions comprising a compound of formula (IA), as  
defined above, as an active principle and a pharmaceutically  
acceptable excipient (which can be a carrier and/or diluent).


The following compounds:

- 4-(1-tetrahylamino)-pyrido[2,3-d]pyrimidine;
  - 7-methoxy-4-(1-tetrahylamino)-pyrido[2,3-d]pyrimidine;
  - 4-(1-tetrahylmethylamino)-pyrido[2,3-d]pyrimidine;
  - 5 7-methoxy-4-(1-tetrahylmethylamino)-pyrido[2,3-d]pyrimidine;
  - 4-(1-tetrahyloxy)-pyrido[2,3-d]pyrimidine;
  - 7-methoxy-4-(1-tetrahyloxy)-pyrido[2,3-d]pyrimidine;
  - 4-(1-tetrahylmethoxy)-pyrido[2,3-d]pyrimidine;
  - 7-methoxy-4-(1-tetrahylmethoxy)-pyrido[2,3-d]pyrimidine;
  - 10 4-(1-tetrahylythio)-pyrido[2,3-d]pyrimidine;
  - 7-methoxy-4-(1-tetrahylythio)-pyrido[2,3-d]pyrimidine;
  - 4-(1-tetrahylmethylthio)-pyrido[2,3-d]pyrimidine;
  - 7-methoxy-4-(1-tetrahylmethylthio)-pyrido[2,3-d]pyrimidine;
  - 4-(1-tetrahylmethyl)-pyrido[2,3-d]pyrimidine; and
  - 15 7-methoxy-4-(1-tetrahylmethyl)-pyrido[2,3-d]pyrimidine;
- either as single isomers or as mixture thereof, which fall within the scope of formula (IA) and have been excluded from the scope of formula (I) by proviso, in view of the general disclosure provided by EP-A-0414386, have never been
- 20 disclosed before as specific chemical entities.

Accordingly, such new compounds of formula (IA), either as single isomers or as a mixture thereof, and the pharmaceutically acceptable salts thereof are a further object of the present invention.

25

An object of the present invention is also to provide the use of a bicyclic condensed pyrimidine compound of formula (IB)



(IB)

wherein

- X is  $-\text{CH}_2-$ ,  $-\text{NH}-(\text{CH}_2)_n-$ ,  $-\text{O}-(\text{CH}_2)_n-$  or  $-\text{S}-(\text{CH}_2)_n-$  in which n is zero or 1;
- 5 A is a 4,5-fused imidazole ring N-substituted by  $\text{R}_3$  which is hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl or benzyl, or A is a 2,3-fused pyridine ring C-substituted by  $\text{R}_4$  which is hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl,  $\text{C}_1$ - $\text{C}_4$  alkoxy, halogen or  $\text{NR}_5\text{R}_6$  in which each of  $\text{R}_5$  and  $\text{R}_6$  independently is H or  $\text{C}_1$ - $\text{C}_4$  alkyl;
- 10 B is a bicyclic ring chosen from tetralin, indane and 2-oxindole;
- each of  $\text{R}_1$  and  $\text{R}_2$ , independently, is hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl, halogen, hydroxy,  $\text{C}_1$ - $\text{C}_4$  alkoxy,  $\text{C}_1$ - $\text{C}_4$  alkoxycarbonyl, nitro, cyano or  $\text{CF}_3$ ;
- 15 or a pharmaceutically acceptable salts thereof for use in the manufacture of a medicament having tyrosine kinase inhibiting activity.

Examples of preferred specific compounds of formula (IB) are  
 20 the following compounds:

- 4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylmethylanino)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethylanino)-pyrido[2,3-
- 25 d]pyrimidine;
- 4-(2-oxindol-5-yloxy)-pyrido[2,3-d]pyrimidine;

- 7-methoxy-4-(2-oxindol-5-yloxy)-pyrido[2,3-d]pyrimidine;  
4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;  
4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;  
5 7-methoxy-4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;  
4-(2-oxindol-5-ylmethylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(2-oxindol-5-ylmethylthio)-pyrido[2,3-  
d]pyrimidine;  
4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;  
10 7-methoxy-4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylamino)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine;  
15 4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;  
20 7-methoxy-4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;  
25 4-(1-tetralylamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralylamino)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylmethylamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralylmethylamino)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralyloxy)-pyrido[2,3-d]pyrimidine;  
30 7-methoxy-4-(1-tetralyloxy)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylmethoxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralylmethoxy)-pyrido[2,3-d]pyrimidine;

- 4-(1-tetralylthio)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(1-tetralylthio)-pyrido[2,3-d]pyrimidine;
- 4-(1-tetralylmethylthio)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(1-tetralylmethylthio)-pyrido[2,3-d]pyrimidine;
- 5 4-(1-tetralylmethyl)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(1-tetralylmethyl)-pyrido[2,3-d]pyrimidine;
- N<sup>6</sup>-(1-tetralyl) adenine;
- N<sup>6</sup>-(3-bromo-1-tetralyl) adenine;
- N<sup>6</sup>-(5-indanyl) adenine;
- 10 N<sup>6</sup>-(7-bromo-5-indanyl) adenine;
- N<sup>6</sup>-(2-oxindol-5-yl) adenine;
- N<sup>6</sup>-(1-tetralylmethyl) adenine;
- N<sup>6</sup>-(5-indanylmethyl) adenine;
- N<sup>6</sup>-(2-oxindol-5-ylmethyl) adenine;
- 15 6-(1-tetralyloxy)-purine;
- 6-(3-bromo-1-tetralyloxy)-purine;
- 6-(5-indanyloxy)-purine;
- 6-(7-bromo-5-indanyloxy)-purine;
- 6-(2-oxindol-5-yloxy)-purine;
- 20 6-(1-tetralylthio)-purine;
- 6-(3-bromo-1-tetralylthio)-purine;
- 6-(5-indanylthio)-purine;
- 6-(7-bromo-5-indanylthio)-purine;
- 6-(2-oxindol-5-ylthio)-purine;
- 25 6-(1-tetralylmethyl)-purine;
- 6-(3-bromo-1-tetralylmethyl)-purine;
- 6-(5-indanylmethyl)-purine;
- 6-(7-bromo-5-indanylmethyl)-purine;
- 6-(2-oxindol-5-ylmethyl)-purine;
- 30 6-(1-tetralylmethoxy)-purine;
- 6-(5-indanylmethoxy)-purine;

6-(2-oxindol-5-ylmethoxy)-purine;  
 6-(1-tetrahylmethylthio)-purine;  
 6-(5-indanylmethylthio)-purine; and  
 6-(2-oxindol-5-ylmethylthio)-purine;


either as single isomers or as a mixture thereof and the pharmaceutically acceptable salts thereof.

Object of the present invention is also to provide a pharmaceutical composition having tyrosine kinase inhibiting activity comprising a pharmaceutically acceptable carrier and/or diluent, and as an active principle a compound of formula (IB) or a pharmaceutically acceptable salt thereof.


The compounds of formula (I), (IA), (IB), and the pharmaceutically acceptable salts thereof, are altogether defined hereafter as the "compounds of the invention" or as the "active agents" of the invention.

The compounds of the invention can be obtained by an analogy process. In particular the compounds of formula (I), and the salts thereof, can be obtained by a process comprising:

a) reacting a compound of formula (II)




wherein A is as defined above and L is a leaving group with an amine compound of formula (III)




wherein n, B, R<sub>1</sub> and R<sub>2</sub> are as defined above, thus obtaining a compound of formula (I) in which X is -NH-(CH<sub>2</sub>)<sub>n</sub>-; or

b) reacting a compound of formula (II) as defined above, with an hydroxy compound of formula (IV)



5 wherein n, B, R<sub>1</sub> and R<sub>2</sub> are as defined above, thus obtaining a compound of formula (I) in which X is -O-(CH<sub>2</sub>)<sub>n</sub>-; or


c) reacting a compound of formula (II) as defined above, with a thio compound of formula (V)



10

wherein n, B, R<sub>1</sub> and R<sub>2</sub> are as defined above, thus giving a compound of formula (I) in which X is -S-(CH<sub>2</sub>)<sub>n</sub>-; or

d) reacting a compound of formula (VI)




15

wherein B, R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are as defined above, with formamide (HCONH<sub>2</sub>), thus providing a compound of formula (I) wherein X is -CH<sub>2</sub>- and A is a 4,5-fused imidazole ring; or

20 e) hydrolyzing and decarboxylating a compound of formula (VII)





wherein B, R<sub>1</sub>, R<sub>2</sub> and R<sub>4</sub> are as defined above, thus providing a compound of formula (I), wherein X is -CH<sub>2</sub>- and A is a 2,3-fused pyridine ring;

5 and, if desired, converting a compound of formula (I) into another compound of formula (I), and/or, if desired, converting a compound of formula (I) into a salt thereof, and/or, if desired, converting a salt of a compound of formula (I) into a free compound of formula (I), and/or, if  
10 desired, separating a mixture of isomers of a compound of formula (I) into the single isomers.

A leaving group L in a compound of formula (II) is for instance chloro, 1,2,4-triazol-1-yl or methylthio.

15 The reaction of a compound of formula (II) with a compound of formula (III) according to process step a) may be carried out using known methods, e.g. as described by Bullock et al. in J. Am. Chem. Soc. 78, 3693 (1956). The reaction is carried out  
20 in the presence of a suitable organic inert solvent, for example an alkanol or ester such as methanol, ethanol, isopropanol, methyl cellosolve or ethyl acetate, a halogenated solvent such as dichloromethane or chloroform, an ether such as tetrahydrofuran or dioxane, a dipolar aprotic  
25 solvent such as dimethylformamide or dimethylacetamide. Preferably the solvents isopropanol or methyl cellosolve are used. The reaction is conveniently carried out at a temperature in the range from about 10 to about 150°C,

preferably in the range from about 20 to about 80°C. In general only 1 equivalent of amine compound (III) is used, thus giving the hydrochloride salt, which precipitates on cooling. To obtain the free base from the salt, the salt may  
5 be treated with a suitable base in the presence of an appropriate solvent such as the ones mentioned above. Suitable bases are e.g. organic amines such as triethylamine or pyridine, or inorganic bases such as sodium carbonate or sodium hydroxide. Alternatively to obtain directly the free  
10 base of formula (I) one may apply more than 2 equivalent of amine compound (III) in the reaction.

The reaction of a compound of formula (II) with a compound of formula (IV) according to process step b) may be carried out  
15 by using known methods, e.g. as described by Prasad et al. in J. Am. Chem. Soc. 79, 6401 (1957). The reaction is preferably carried out in a protic solvent, e.g. water or aqueous alkanol such as aqueous methanol, ethanol or isopropanol in the presence of a suitable alkali base such as sodium or  
20 potassium hydroxide. The reaction temperatures are ranging from about 0 to about 100°C, preferably the range is from about 50 to about 100°C. Alternatively the hydroxy compound of formula (IV) is at first transformed into its metal salt in an aprotic solvent, which is then reacted with the  
25 compound of formula (II). For example the metallation of compound (IV) may be carried out with metal compounds like NaH or NaNH<sub>2</sub> in an aprotic solvent such as tetrahydrofuran, ethyl ether, DMF or benzene. The metal salt is then reacted with compound (II) in the same aprotic solvent at  
30 temperatures ranging from about 0 to about 100°C, preferably in the range from about 20 to about 40°C.

The reaction of a compound of formula (II) with a thiol

compound of formula (V) according to process step c) may be carried out using known methods, e.g. as reviewed in Heterocyclic Compounds vol.8, page 335 (1967, Editor R.C. Elderfield). Suitable reaction solvents are protic solvents, e.g. water, alkanols such as methanol, ethanol and isopropanol or ethers such as tetrahydrofuran or dioxane. In order to obtain the corresponding metal mercaptide, which is the actual reactant, the reaction is carried out in the presence of a suitable alkali base, e.g. an alkali hydroxide such as sodium or potassium hydroxide, an alkali alkoxide such as sodium or potassium methoxide, sodium or potassium ethoxide or sodium or potassium methoxyethoxide. The reaction temperature may vary from about 0 to about 120°C, preferably from about 40 to about 80°C.

The cyclization of the ortho diamino compound of formula (VI) according to process step d) may be carried out by known methods, e.g. as reviewed in Rodd's Chemistry of Carbon Compounds vol.IV, part L, page 5 (1980, Elsevier Scientific Publishing Company). Hereto an important modification of the Traube cyclization method can be applied which uses formamide instead of formic acid, e.g. as described by Daly et al. in J.Org.Chem. 21, 177 (1956). Accordingly the compound (VI) is cyclized in formamide solution at temperatures ranging from about 100 to about 210°C, preferably at reflux temperature.

The hydrolysis and decarboxylation of a compound of formula (VII) according to process step e) may be carried out using known methods, e.g. as described in J.Het.Chem. 14, 1081 (1977) by A.Scoville and F.X.Smith. Suitable reaction solvents are protic solvents, e.g. water or aqueous alkanols

such as methanol, ethanol or isopropanol. The hydrolysis step is carried out in alkaline conditions, e.g. in the presence of an alkali hydroxide such as sodium or potassium hydroxide. The reaction temperature may range from room to reflux temperature, preferably reflux temperature is applied. The decarboxylation step is carried out in slightly acidic conditions, e.g. in the presence of a mineral acid such as hydrochloric acid. The reaction temperature may vary from room to reflux temperature, preferably reflux temperature is used.

The optional salification of a compound of formula (I) as well as the conversion of the salt into the corresponding free compound and the separation of the mixture of isomers into the single isomers as well as the conversion of a compound of formula (I) into another compound of formula (I) may be carried according to known methods.


The conversion of a compound of formula (I), wherein A is a 4,5-fused imidazole ring and  $R_3$  is H, into the respective compound of formula (I), wherein  $R_3$  is  $C_1$ - $C_4$  alkyl or benzyl, may be carried out by known N-alkylation methods, e.g. as mentioned in Heterocyclic Compounds vol.8, page 378 (1967, editor R.C. Elderfield). Accordingly a  $C_1$ - $C_4$  alkyl or benzyl halide is reacted with the  $N^9$ -unsubstituted purine in an appropriate organic solvent, preferably in a dipolar aprotic solvent such as DMF, DMAA or DMSO, and in the presence of an inorganic base such as sodium hydroxide or potassium carbonate.

30

The conversion of a compound of formula (I), wherein X is  $-O-(CH_2)_n-$  or  $-S-(CH_2)_n-$  into a compound (I), wherein X is

-NH-(CH<sub>2</sub>)<sub>n</sub>- can be carried out, according known methods, by a displacement reaction with an amine compound of formula (III) as defined above. E.g. according to Elion et al. in J.Am.Chem.Soc. 74, 411 (1952) the thio compound of formula (I) is heated with the amine compound of formula (III) in aqueous solution in a sealed tube at temperatures ranging from about 130 to about 180°C.


The compounds of formula (II), wherein A is a 4,5-fused imidazole ring and L is chloro, are known or may be obtained from a compound of formula (VIII)



by known N-alkylation methods, e.g. as reviewed in Heterocyclic Compounds vol.8, page 372 (1967, Editor R.C.Elderfield) and as mentioned above.

The compound of formula (VIII) is commercially available.

The compounds of formula (II), wherein A is a 2,3-fused pyridine ring, are known or may be obtained by known methods from known compounds. For example the 4-chloro compounds of formula (II), wherein A is a 2,3-fused pyridine ring and L is chloro are prepared by chlorodehydroxylation of the corresponding 4-hydroxy-pyrido[2,3-d]pyrimidine derivatives of formula (IX)




using conventional methods, e.g. by reaction with POCl<sub>3</sub>. The intermediate of formula (II), wherein A is a 2,3-fused

pyridine ring and L is 1,2,4-triazol-1-yl, can be prepared e.g. by adding gradually  $\text{POCl}_3$  to a mixture of compound of formula (IX) (1 equivalent) and 1,2,4-triazole (3 equivalent) in pyridine solution at temperatures ranging from room to reflux temperatures.

The compounds of formula (IX) are known or may be obtained by known methods from known compounds. For example 4-hydroxy pyrido[2,3-d]pyrimidine is obtained from 2-aminonicotinic acid by condensation with formamide as described in J. Am. Chem. Soc. 77, 2256 (1955) by R.K. Robins and G.H. Hitchings.

The compounds of formula (VII) can be made by using the process of A. Scoville and F.X. Smith as described in J. Het. Chem. 14, 1081 (1977). Accordingly a compound of formula (II), in which L is chloro, A is a 2,3-fused pyridine ring and  $R_4$  is as defined above, is reacted with a compound of formula (X)



in which B,  $R_1$  and  $R_2$  are as defined above.

The compounds of formulae (III), (IV), (V), (VI), and (X) are either known compounds or may be obtained by known methods from known compounds.

When in the new compounds of the present invention and in the intermediate products used for their preparation there are groups present which need to be protected before the above-described reactions are performed, they may be protected before the reaction takes place and then deprotected at the

end of the reaction, according to well known methods in organic chemistry.

The new compounds of formula (IA) can be analogously obtained.

5

#### PHARMACOLOGY

The compounds of the invention possess specific tyrosine kinase inhibiting activity. It is believed that tyrosine kinase inhibitors may be of great importance in the control  
10 of uncontrolled cellular reproduction, i.e. in cellular reproduction disorders. Hence, the compounds according to the present invention can be useful in the treatment of pathological proliferation disorders in mammals, including humans. Typical examples of such disorders are tumors,  
15 including leukemia, and psoriasis. The compounds of the invention can also be useful in inhibiting the development of the atheromatous plaque and in the control of angiogenesis and as anti-metastatic agents.

Recent studies on the molecular basis of the neoplastic  
20 transformation have identified a family of genes, designed oncogenes, whose aberrant expression causes tumorigenesis. For example, the RNA tumor viruses possess such an oncogene sequence whose expression determines neoplastic conversion of infected cells. Several of their oncogene-encoded proteins,  
25 such as pp60<sup>v</sup>-src, p70<sup>gag</sup>-yes, p130<sup>gag</sup>-fps and p70<sup>gag</sup>-fgr display protein tyrosine kinase activity, that is they catalyze the transfer of the  $\gamma$ -phosphate from adenosine triphosphate (ATP) to tyrosine residues in protein substrate. In normal cells, several growth factor receptors, for example  
30 the receptors for PDGF, EGF,  $\alpha$ -TGF and insulin, display tyrosine kinase activity. Binding of the growth factor (GF) activates the receptor tyrosine kinase to undergo

autophosphorylation and to phosphorylate closely adjacent molecules on tyrosine. Therefore, it is thought that the phosphorylation of these tyrosine kinase receptors plays an important role in signal transduction and the principal function of tyrosine kinase activity in normal cells is to regulate cell growth. Perturbation of this activity by oncogenic tyrosine kinases that are either overproduced and/or display altered substrate specificity may cause loss of growth control and/or neoplastic transformation. Accordingly, a specific inhibitor of tyrosine kinase can be useful in investigating the mechanism of cancerogenesis, cell proliferation and differentiation and it can be effective in the prevention and chemotherapy of cancer and in other pathological proliferative conditions.

Hence the compounds according to the present invention can be useful in the treatment of pathological proliferation disorders in mammals, including humans.

A human or animal, e.g. a mammal, can thus be treated by a method comprising the administration thereto of a therapeutically effective amount of one of the compounds of the invention. In this way the condition of the human or animal may be improved. Amelioration of the disease state or disorder from which the human or animal is suffering can be achieved. Typical examples of such disorders are benign and malignant tumours, including leukemia such as myeloblastic leukaemia, lymphoma, sarcoma, neuroblastoma, Wilm's tumour, malignant neoplasm of the bladder, breast, lung or thyroid, neoplasias of epithelial origin, such as mammary carcinoma. Moreover, they can be useful in the treatment of epidermal hyperproliferation, such as psoriasis. The compounds of the invention can also be useful in inhibiting the development of the atheromatous plaque and restenosis, in the control of



angiogenesis, as anti-metastatic agents and in treating diabetic complications. They have also utility in the control of immune system diseases, e.g. as immunosuppressants, as far as protein tyrosine kinases, particularly Zap70, p56 lck and p59 fyn, are strongly involved in the control of the proliferation of the immune system. Moreover, the compounds of the invention have utility in the treatment of Alzheimer's disease due to the pivotal role played by tyrosine phosphorylation (e.g. Tau proteins) in the development of the disease.

The tyrosine specific protein kinase activity of the compounds of the invention is shown, e.g., by the fact that they are active in the in vitro and in vivo test described herebelow.

#### EGFR-Autophosphorylation Assay (AMKA assay)

The EGFR autophosphorylation was assayed using A431 crude membrane extracts as source of the receptor.

#### Membrane purification:

Membranes were prepared as reported by A. Levitzky et al. (Methods in Enzymology 201, 347 (1991) with minor modifications and adapting the method to the A431 human epidermoid carcinoma cell line. Briefly, low density cells growing in RPMI 1640 plus 10% foetal calf serum were detached using 1 mM EDTA in phosphate buffer saline (PBS) and lysed in cold Lysing buffer (1 ml/10<sup>6</sup> cells) (20 mM HEPES pH 7.6, 10 mM NaCl, 2 mM EDTA, 10 µg/ml Aprotinin, 10 µg/ml Luepeptin, 1 mM PMSF). Cells were homogenized by 10 strokes in Dounce homogenizer. Nuclei and debris were removed by low speed centrifugation. Membranes were pelletized by ultracentrifugation (1 h, 100000 x g) and resuspended in cold HNG buffer (50 mM HEPES pH 7.6, 125 mM NaCl, 10% glycerol).

Protein concentration, determined by Pierce BCA method, was adjusted to 1.5-2 mg/ml. Aliquots were stored at -80°C.

#### Determination of IC<sub>50</sub>:

To determine the IC<sub>50</sub> A431 membranes (2.5 mg of protein/sample) pre-treated with EGF (final concentration 200 nM) for 30 min at 4°C were incubated in 30 µl of reaction buffer (50 mM HEPES pH 7.6, 125 mM NaCl, 12 mM Mg-acetate, 2 mM MnCl<sub>2</sub>, 1 mM NaVO<sub>3</sub>, 1 mM ATP, 1 mCi γ <sup>32</sup>P-ATP) for 1 min at 0°C in the presence of increasing concentrations of compounds. The reaction was stopped with Laemly solution. The samples were heated 5 min at 95°C and submitted to SDS-PAGE (7.5% acrylamide gel). Gels were fixed in 40% methanol:10% acetic acid for 1 h and washed overnight with 20% methanol:7% acetic acid. After 15 min in 50% methanol:2% glycerol gels were dried and exposed overnight. Bands corresponding to EGFR were excised from the gels and counted in a β-counter.

#### Inhibition of cellular tyrosine autophosphorylation (VAP assay)

EGF is able to induce the phosphorylation in tyrosine of a specific set of intracellular proteins including EGFR itself. This increase in tyrosine phosphorylation was measured using the Vectastain-ABC-AP kit (Vector Laboratories) following the manufacturer's instructions. Briefly, 2 x 10<sup>4</sup> A431 cells per well were plated into a microtiter plate and incubated for 3 days at 37°C/ 5% CO<sub>2</sub> until the cultures reached confluency. Cell monolayers were washed with PBS and covered with fresh medium containing 0.1% bovine serum albumin (BSA). Serial dilution of test compounds were added 2 h before the addition of 100 ng/ml EGF; after 10 min stimulation the culture medium was withdrawn, cells were washed 2 times with PBS and fixed

for 10 min with cold methanol (-20°C). After fixation 200 ml of blocking solution (3% BSA in PBS, 0.2% Tween 20, 1% normal horse serum) were added for 1 h at 37°C. Blocking solution was replaced with 3% BSA in PBS containing the anti-phosphotyrosine antibody 4G10 (UBI) diluted 1:30000 and incubated for 1 h. Bound antibodies were revealed using the Vectastain-ABC-AP kit with p-nitrophenyl phosphate as the substrate. Reaction was developed for 30 min in the dark and the plates were read at 405 nm.

10

#### SRB-Antiproliferative assay (A431 assay)

The antiproliferative activity of the test compounds was assayed on A431 cells using the SRB colorimetric method (P. Skehan et al.: J.Natl.Cancer Inst.1990, 82, 1107-1112). A431 cells were seeded into 96-well microtiter plates (5000 cells/cm<sup>2</sup>) and incubated overnight at 37°C/5% CO<sub>2</sub>. Compounds dissolved in DMSO were added in serial dilution and plates were incubated for 3 days at 37°C/5% CO<sub>2</sub>. Cells were fixed with cold TCA (10% final concentration) and stained with 0.4% Sulforhodamine B dye in 1% acetic acid for 30 min. Dye was solubilized with 10 mM Tris (pH 10.4) and microtiter plates were read at 550 nm.

In view of their high activity, the compounds of the invention can be used safely in medicine.

The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the forms of tablets, capsules, sugar- and film-coated tablets, liquid solutions or suspensions; rectally, in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous injection or infusion; or topically. The dosage depends on the age, weight, condition of the patient and administration route. For example, the dosage adopted for

30

oral administration to adult humans for the compounds 4-(5-indanylamino)-pirido[2,3-d]pyrimidine and N<sup>6</sup>-(1-tetralyl)-adenine may range from about 5 to about 150-200 mg per dose, from 1 to 5 times daily. Of course, these dosage regimes may be adjusted to provide the optimal therapeutic response.

The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.

For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate, effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, by means of mixing, granulating, tableting, sugar-coating or film-coating processes.

The liquid dispersion for oral administration may be, e.g., syrups, emulsions and suspensions.

The syrup may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol.

The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.

The solutions for intravenous injections or infusions may contain as carrier, for example, sterile water or, preferably, they may be in the form of sterile aqueous, isotonic saline solutions.

The suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. cocoa-butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.

Compositions for topical application, e.g. creams, lotions or pastes, can be prepared by admixing the active ingredient with a conventional oleaginous or emulsifying excipient.

A further object of the present invention is a combined method of treatment of cancer or of amelioration of the conditions of mammals, including humans, suffering from cancer, said method comprising administering

- 1) a compound of the invention, that is a compound of formula (I), (IA) or (IB) or a pharmaceutically acceptable salt thereof, and
- 2) an additional antitumor agent, in amounts and close enough together in time sufficient to produce a therapeutically useful effect.

The present invention also provides products containing a compound of the invention, that is a compound of formula (I), (IA) or (IB) or a pharmaceutically acceptable salt thereof, and an additional antitumor agent as a combined preparation for simultaneous, separate or sequential use in anticancer

therapy.

The term "antitumour agent" is meant to comprise both a single antitumour drug and "cocktails", i.e. a mixture of such drugs, according to the clinical practice

5. Examples of antitumour agents that can be formulated with a compound of the invention or, alternatively, can be administered in a combined method of treatment, include doxorubicin, daunomycin, epirubicin, idarubicin, etoposide, fluorouracil, melphalan, cyclophosphamide, bleomycin, 10 vinblastin and mitomycin or a mixture of two or more thereof.

The compounds of the invention can therefore be used in a treatment to ameliorate a cancer. They may be administered to a patient suffering from a cancer treatable with an antitumour agent, for example an anthracycline glycoside such 15 as doxorubicin, daunomycin, epirubicin or idarubicin as mentioned above, together with the antitumour agent.

A compound of the invention and an antitumour agent such as an anthracycline glycoside can be administered to improve the condition of a patient having leukemia such as myeloblastic 20 leukemia, lymphoma, sarcoma, neuroblastoma, Wilm's tumour or malignant neoplasm of the bladder, breast, lung or thyroid.

Accordingly, the present invention provides a method of treating a patient in need of a tyrosine kinase inhibitor, the method comprising administering to said patient a 25 therapeutically effective amount of a compound of formula (I), (IA) or of formula (IB), as defined above, or a pharmaceutically acceptable salt thereof.

The following examples illustrate but do not limit the invention.

Example 1**4-(5-indanylamino)-pyrido[2,3-d]pyrimidine hydrochloride**

A solution of 6-chloropyrido[2,3-d]pyrimidine (1.656 g, 10 mM) and 5-aminoindan (1.332 g, 10 mM) in isopropanol (60 ml) is heated to reflux for about 20 h. The resulting salt suspension is then cooled to room temperature, filtered and the residue washed with ice-cooled isopropanol to give almost pure title compound in about 80 % yield.

10  $C_{16}H_{15}ClN_4$  calcd: C64.32 H5.06 Cl 11.86 N18.75  
found: C64.05 H4.96 Cl 11.65 N18.55

MS m/z 298

According to the above described procedure the following  
15 compounds can be prepared:

7-methoxy-4-(5-indanylamino)-pyrido[2,3-d]pyrimidine  
hydrochloride;

4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine  
hydrochloride

20 7-methoxy-4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine  
hydrochloride;

4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine  
hydrochloride;

7-methoxy-4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine  
25 hydrochloride;

4-(2-oxindol-5-ylmethylamino)-pyrido[2,3-d]pyrimidine  
hydrochloride;

7-methoxy-4-(2-oxindol-5-ylmethylamino)-pyrido[2,3-  
d]pyrimidine hydrochloride;

30 4-(1-tetrahydrylamino)-pyrido[2,3-d]pyrimidine hydrochloride;  
7-methoxy-4-(1-tetrahydrylamino)-pyrido[2,3-d]pyrimidine  
hydrochloride;

4 (1-tetrahylmethylamino) pyrido[2,3-d]pyrimidine  
hydrochloride; and  
7-methoxy-4-(1-tetrahylmethylamino)-pyrido[2,3-d]pyrimidine  
hydrochloride.

5

**Example 2****4-(5-indanylamino)-pyrido[2,3-d]pyrimidine**

A suspension of 4-(5-indanylamino)-pyrido[2,3-d]pyrimidine  
10 hydrochloride (2.988 g, 10 mM) and potassium carbonate (2.764  
g, 20 mM) in methanol (60 ml) is stirred at ambient  
temperature for 0.5 h. The mixture is filtered and the  
filtrate evaporated under vacuum. The residue is purified by  
column chromatography using a 93:7 mixture of  
15 dichloromethane/methanol as eluant to give pure title  
compound in 90 % yield.

C<sub>16</sub>H<sub>14</sub>N<sub>4</sub> calcd: C73.26 H5.38 N21.36

found: C73.15 H5.25 N21.15

MS m/z 262

20

By proceeding analogously the following compounds can be  
prepared:

7-methoxy-4-(5-indanylamino)-pyrido[2,3-d]pyrimidine;

4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine;

25 7-methoxy-4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine;

4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;

7-methoxy-4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;

4-(2-oxindol-5-ylmethylamino)-pyrido[2,3-d]pyrimidine;

7-methoxy-4-(2-oxindol-5-ylmethylamino)-pyrido[2,3-

30 d]pyrimidine

4-(1-tetrahylamino)-pyrido[2,3-d]pyrimidine;

7-methoxy-4-(1-tetrahylamino)-pyrido[2,3-d]pyrimidine;



4-(1-tetralylmethylamino)-pyrido[2,3-d]pyrimidine; and  
7-methoxy-4-(1-tetralylmethylamino)-pyrido[2,3-d]pyrimidine.

**Example 3**

**5 4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine**

To a solution of 5-hydroxyindan (1.342 g, 10mM) in 80 ml of  
aqueous potassium hydroxide solution containing 1.683 g (30  
mM) of solid potassium hydroxide is added 6-chloro-  
10 pyrido[2,3 d] pyrimidine (1.656 g, 10 mM). The reaction  
mixture is stirred for about 0.5 h at room temperature until  
most of the 6-chloro-pyrido[2,3-d]pyrimidine dissolves and  
then heated on the steam bath for further 0.5 h. The mixture  
is cooled, filtered and the residue recrystallized from hot  
15 aqueous ethanol to give pure title compound in 60 % yield.

$C_{16}H_{13}N_3O$  calcd: C72.99 H4.97 N15.96

found: C72.65 H4.91 N15.85

MS m/z 263

20 According to the above described procedure the following  
compounds can be prepared:

- 4-(2-oxindol-5-yloxy)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-yloxy)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;
- 25 7-methoxy-4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;
- 4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;
- 4-(1-tetralyloxy)-pyrido[2,3-d]pyrimidine;
- 30 7-methoxy-4-(1-tetralyloxy)-pyrido[2,3-d]pyrimidine;
- 4-(1-tetralylmethyloxy)-pyrido[2,3-d]pyrimidine; and
- 7-methoxy-4-(1-tetralylmethyloxy)-pyrido[2,3-d]pyrimidine.

**Example 4****4-(5-indanylthio)-pyrido[2,3-d]pyrimidine**

To a solution of 6-chloropyrido[2,3-d]pyrimidine (1.656 g, 10 mm) in methanol (30 ml) is added a solution of 1-mercaptoindan (4.506 g, 30 mm) in methanolic potassium hydroxide (60 ml containing 1.608g (30 mm) solid potassium hydroxide). The reaction mixture is stirred for 0.5 h at room temperature and then boiled for 0.5 h at reflux. The solution is concentrated under vacuum and then cooled to give crystalline title compound in about 60 % yield.

$C_{16}H_{13}N_3S$  calcd: C68.79 H4.69 N15.04 S11.48

found: C68.65 H4.55 N14.75 S11.30

MS m/z 279

By proceeding analogously the following compounds can be prepared:

4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;

7-methoxy-4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;

4-(2-oxindol-5-ylmethylthio)-pyrido[2,3-d]pyrimidine;

7-methoxy-4-(2-oxindol-5-ylmethylthio)-pyrido[2,3-d]pyrimidine;

7-methoxy-4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;

4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;

7-methoxy-4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;

4-(1-tetralylthio)-pyrido[2,3-d]pyrimidine;

7-methoxy-4-(1-tetralylthio)-pyrido[2,3-d]pyrimidine;

4-(1-tetralylmethylthio)-pyrido[2,3-d]pyrimidine; and

7-methoxy-4-(1-tetralylmethylthio)-pyrido[2,3-d]pyrimidine.

**Example 5****4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine**

A solution of 5-(5-indanyl)-5-(pyrido[2,3-d]pyrimidin-4-yl) barbituric acid (3.734 g, 10 mM) and sodium hydroxide (2.00 g, 50 mM) in water (40 ml) is refluxed for 15 h. After cooling the solution is made slightly acidic (pH4-5) by addition of HCl and again refluxed for 15 h. The solution is cooled, made strongly basic with sodium hydroxide and then extracted with ethyl acetate. The organic phase is washed with water, dried and then evaporated to dryness under vacuum. The residue is purified by column chromatography using dichloromethane/methanol 93:7 as eluant. Thus pure title compound is obtained in about 60 % yield.

By proceeding analogously the following compounds can be prepared:

- 4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;
- 4-(1-tetralylmethyl)-pyrido[2,3-d]pyrimidine; and
- 7-methoxy-4-(1-tetralylmethyl)-pyrido[2,3-d]pyrimidine.

#### Example 6

##### **4-(5-indanylamino)-pyrido[2,3-d]pyrimidine**

A suspension of 4-(5-indanylthio)-pyrido[2,3-d]pyrimidine (2.79 g, 10 mM) and 5-aminoindan (3.996 g, 30 mM) in water (100 ml) is heated in a sealed tube at 130°C for 20 h. Then the water is evaporated under vacuum and the residue chromatographed on silica gel by using dichloromethane/methanol mixtures as eluant. Thus almost pure title compound is obtained in about 40 % yield.

C<sub>16</sub>H<sub>14</sub>N<sub>4</sub> calcd: C73.26 H5.38 N21.36

found: C73.01 H5.15 N21.05

MS m/z 262

**Example 7**

**5-(5-indanyl)-5-(pyrido[2,3-d]pyrimidin-4-yl) barbituric acid**

5

A slurry of 4-chloro-pyrido[2,3-d]pyrimidine (1.656 g, 10 mM) and 5-(5-indanyl) barbituric acid (2.443 g, 10 mM) is stirred in an oil bath. The temperature is raised to 130°C in a period of 15 min. Then the temperature is further increased from 130°C to 170°C. During this period apparently a reaction occurs since the slurry solidifies. The resulting solid is maintained for further 10 min at about 170°C. Then the reaction mixture is cooled, triturated with sodium bicarbonate solution and hexane. The solid is filtered off, washed with water and dried under vacuum. The raw product is submitted to the next step without further purification.

**Example 8**

**4-chloro-pyrido[2,3-d]pyrimidine**

20

A mixture of pyrido[2,3-d]pyrimidin-4(3H)-one (1.471 g, 10 mM) and POCl<sub>3</sub> (16 ml) is stirred for 1 h at reflux. The excess of POCl<sub>3</sub> is removed under vacuum. Then dichloromethane and iced water is added and the mixture stirred until the black solid dissolves. The organic layer is separated, washed with bicarbonate solution, dried over Na<sub>2</sub>SO<sub>4</sub> and then evaporated to dryness. The yellow residue is recrystallized from toluene / hexane to give almost pure title compound in 70 % yield. mp 137°C.

Example 9

## Pyrido[2,3-d]pyrimidin-4(3H)-one

2-aminonicotinic acid (1.381 g, 10 mM) and formamide (2.70 g, 60 mM) are heated at 165-170°C for 2 h by means of an oil bath. The reaction mixture is cooled and the resulting solid recrystallized from water to give about 1.030 g of title compound (70 % yield). mp 255-8°C.

10 Example 10N<sup>6</sup>-(1-tetralyl) adenine hydrochloride salt

A solution of 6-chloropurine (1.546 g, 10 mM) and 1-aminotetralin (1.472 g, 10 mM) in isopropanol (60 ml) is heated to reflux for about 20 h. The resulting salt suspension is then cooled to room temperature, filtered and the residue washed with ice-cooled isopropanol to give almost pure title compound in 80 % yield.

C<sub>15</sub>H<sub>16</sub>ClN<sub>5</sub> calcd: C59.70 H5.34 Cl11.75 N23.21

20 found: C59.65 H5.25 Cl11.65 N23.15

MS m/z 301

NMR δ ppm (DMSO-d<sub>3</sub>): 1.70 (m, 4H), 2.6-2.9 (m, 4H), 7.0-7.3 (m, 3H), 8.46, 8.62 (two s, 2H), 10.9 (bs, 1H).

25 According to the above described procedure the following compounds can be prepared:

N<sup>6</sup>-(3-bromo-1-tetralyl) adenine hydrochloride;

N<sup>6</sup>-(5-indanyl) adenine hydrochloride;

N<sup>6</sup>-(7-bromo-5-indanyl) adenine hydrochloride;

30

N<sup>6</sup>-(2-oxindol-5-yl) adenine hydrochloride:

$C_{13}H_{11}ClN_5O$  calcd: C51.59 H3.66 Cl 11.71 N27.76  
found: C51.50 H3.51 Cl 11.55 N27.45

MS m/z 302

NMR  $\delta$  ppm (DMSO- $d_6$ ): 3.53 (s, 2H), 6.86 (d, J=8.3Hz, 1H),  
5 6.52 (dd, J=2.2 and 8.3Hz, 1H), 7.68 (d, J=2.2Hz, 1H), 8.59,  
8.62 (two s, 2H), 10.45 (s, 1H), 11.1 (bs, 1H);

N<sup>6</sup>-(1-tetralylmethyl) adenine hydrochloride;

N<sup>6</sup>-(5-indanylmethyl) adenine hydrochloride; and

10 N<sup>6</sup>-(2-oxoindol-5-ylmethyl) adenine hydrochloride.

#### Example 11

N<sup>6</sup>-(1-tetralyl) adenine

15 A suspension of N<sup>6</sup>-(1-tetralyl) adenine hydrochloride salt  
(3.018 g, 10 mM) and potassium carbonate (2.764 g, 20 mM) in  
methanol (60 ml) is stirred at ambient temperature for 0.5 h.  
The mixture is filtered and the filtrate evaporated under  
vacuum. The residue is purified by column chromatography  
20 using a 93:7 mixture of dichloromethane/methanol as eluant to  
give pure title compound in 90 % yield.

$C_{15}H_{15}N_5$  calcd: C67.91 H5.70 N26.39

found: C67.65 H5.61 N26.25

MS m/z 265

25

By proceeding analogously the following compounds can be  
prepared:

N<sup>6</sup>-(3-bromo-1-tetralyl) adenine;

N<sup>6</sup>-(5-indanyl) adenine;

30 N<sup>6</sup>-(7-bromo-5-indanyl) adenine;

N<sup>6</sup>-(2-oxindol-5-yl) adenine;  
N<sup>6</sup>-(1-tetralylmethyl) adenine;  
N<sup>6</sup>-(5-indanylmethyl) adenine; and  
N<sup>6</sup>-(2-oxindol-5-ylmethyl) adenine.

5

Example 12**6-(1-tetralyloxy)-purine**

To a solution of 1-hydroxytetralin (1.482 g, 10mm) in 80 ml  
10 of aqueous potassium hydroxide solution containing 1.683 g  
(30 mm) of solid potassium hydroxide is added 6-chloropurine  
(1.546 g, 10 mm). The reaction mixture is stirred for about  
0.5 h at room temperature until most of the 6-chloropurine  
dissolves and then heated on the steam bath for further 0.5  
15 h. The mixture is cooled, filtered and the residue  
recrystallized from hot aqueous ethanol to give pure title  
compound in 60 % yield.

C<sub>15</sub>H<sub>14</sub>N<sub>4</sub>O calcd: C67.65 H5.30 N21.04

found: C67.55 H5.25 N20.95

20 MS m/z 266

According to the above described procedure the following  
compounds can be prepared:

- 6-(3-bromo-1-tetralyloxy)-purine;
- 25 6-(5-indanyloxy)-purine;
- 6-(7-bromo-5-indanyloxy)-purine;
- 6-(2-oxindol-5-yloxy)-purine;
- 6-(1-tetralylmethoxy)-purine;
- 6-(5-indanylmethoxy)-purine; and
- 30 6-(2-oxindol-5-ylmethoxy)-purine.

Example 13

## 6-(1-tetralylthio)-purine

To a solution of 6-chloropurine (1.546 g, 10 mM) in methanol (30 ml) is added a solution of 1-mercaptotetralin (4.929 g, 30 mM) in methanolic potassium hydroxide (60 ml containing 1.608g (30 mM) solid potassium hydroxide). The reaction mixture is stirred for 0.5 h at room temperature and then boiled for 0.5 h at reflux. The solution is concentrated under vacuum and then cooled to give crystalline title compound in about 60 % yield.

C<sub>15</sub>H<sub>14</sub>N<sub>4</sub>S calcd: C63.81 H5.00 N19.84 S11.35

found: C63.65 H4.95 N19.75 S11.30

MS m/z 282

By proceeding analogously the following compounds can be prepared:

6-(3-bromo-1-tetralylthio)-purine;

6-(5-indanylthio)-purine;

6-(7-bromo-5-indanylthio)-purine;

6-(2-oxoindol-5-ylthio)-purine;

6-(1-tetralylmethylthio)-purine;

6-(5-indanylmethylthio)-purine; and

6-(2-oxindol-5-ylmethylthio)-purine.

Example 14

## 6-(1-tetralylmethyl)-purine

A solution of 4,5-diamino-6-(1-tetralylmethyl)-pyrimidine sulfate (3.523 g, 10 mM) in formamide (30 ml) is heated to reflux for 0.5 h. The mixture is cooled, diluted with water and neutralized with aqueous sodium carbonate. The



precipitate is removed by filtration and recrystallized from aqueous ethanol to yield pure title compound in about 70 % yield.

C<sub>16</sub>H<sub>16</sub>N<sub>4</sub> calcd: C72.70 H6.10 N21.20

5 found: C72.55 H6.05 N21.05

MS m/z 264

By proceeding analogously the following compounds can be prepared:

10 6-(3-bromo-1-tetralylmethyl)-purine;

6-(5-indanylmethyl)-purine;

6-(7-bromo-5-indanylmethyl)-purine; and

6-(2-oxindol-5-ylmethyl)-purine.

15 Example 15

**N<sup>6</sup>-(1-tetralyl) adenine**

A suspension of 6-(1-tetralylthio)-purine(2.82 g, 10 mM) and 1-aminotetralin (4.416 g, 30 mM) in water (100 ml) is heated  
20 in a sealed tube at 130°C for 20 h. Then the water is evaporated under vacuum and the residue chromatographed on silica gel by using dichloromethane/methanol mixtures as eluant. Thus almost pure title compound is obtained in about 40 % yield.

25 C<sub>15</sub>H<sub>15</sub>N<sub>5</sub> calcd: C67.91 H5.70 N26.39

found: C67.85 H5.45 N26.35

MS m/z 265

By proceeding analogously the following compounds can be  
30 prepared:

N<sup>6</sup>-(3-bromo-1-tetralyl) adenine;

- $N^6$ -(5-indanyl) adenine;  
 $N^6$ -(7-bromo-5-indanyl) adenine;  
 $N^6$ -(2-oxindol-5-yl) adenine;  
 $N^6$ -(1-tetralylmethyl) adenine;  
5  $N^6$ -(5-indanylmethyl) adenine, and  
 $N^6$ -(2-oxindol-5-ylmethyl) adenine.

#### Example 16

##### **9-benzyl- $N^6$ -(1-tetralyl)-adenine**

10

A solution of  $N^6$ -(1-tetralyl) adenine (2.05 g, 10 mM) and benzylchloride (2.53 g, 20 mM) in dimethyl acetamide (DMAA, 100 ml) containing dry potassium carbonate (1.382 g, 10 mM) in suspension is heated with stirring for 16 h at 110°C.  
15 After filtration the solution is evaporated to dryness in vacuum and the residue is crystallized from ethanol to give pure title compound in about 50 % yield.

$C_{22}H_{21}N_5$  calcd: C74.34 H5.96 N19.70

found: C74.21 H5.85 N19.55

20 MS m/z 355

#### Example 17

##### **9-ethyl-6-chloropurine**

25 To a solution of 6-chloropurine (1.545 g, 10 mM) and iodoethane (3.22 g, 20 mM) in DMSO (50 ml) is added potassium carbonate (1.382 g, 10 mM). The resulting suspension is stirred for 2 h at room temperature, then diluted with water and extracted 3 times with ether. The ether extract is  
30 evaporated and the residue is purified by column chromatography using dichloromethane/ethanol 95:5 as eluant.

Thus pure title compound is obtained in about 50 % yield.

$C_5H_7ClN_4$  calcd: C37.87 H4.45 Cl22.35 N35.33

found: C37.75 H4.35 Cl22.21 N35.30

MS m/z 158

5

#### Example 18

Tablets each weighing 0.150 g and containing 25 mg of the active substance, can be manufactured as follows:

10 Composition (for 10,000 tablets):

$N^6$ -(1-tetralyl) adenine	250 g
Lactose	800 g
Corn starch	415 g
Talc powder	30 g
15 Magnesium stearate	5 g

The  $N^6$ -(1-tetralyl) adenine, the lactose and half of the corn starch are mixed; the mixture is then forced through a sieve of 0.5 mm mesh size. Corn starch (10 g) is suspended in warm  
20 water (90 ml) and the resulting paste is used to granulate the powder. The granulate is dried, comminuted on a sieve of 1.4 mm mesh size, then the remaining quantity of starch, talc and magnesium stearate is added, carefully mixed and processed into tablets.

25

#### Example 19

Capsules, each dosed at 0.200 g and containing 20 mg of the active substance can be prepared.

30 Composition for 500 capsules:

N <sup>6</sup> -(5-indanyl) adenine	10 g
Lactose	80 g
Corn starch	5 g
Magnesium stearate	5 g

This formulation is encapsulated in two-piece hard gelatin capsules and dosed at 0.200 g for each capsule.

#### Example 20

Tablets each weighing 0.150 g and containing 25 mg of the active substance, can be manufactured as follows:

Composition (for 10,000 tablets):

4-(5-indanylamino)-pyrido[2,3-d]pyrimidine	250 g
Lactose	800 g
Corn starch	415 g
Talc powder	30 g
Magnesium stearate	5 g

The 4-(5-indanylamino)-pyrido[2,3-d]pyrimidine, the lactose and half of the corn starch are mixed; the mixture is then forced through a sieve of 0.5 mm mesh size. Corn starch (10 g) is suspended in warm water (90 ml) and the resulting paste is used to granulate the powder. The granulate is dried, comminuted on a sieve of 1.4 mm mesh size, then the remaining quantity of starch, talc and magnesium stearate is added, carefully mixed and processed into tablets.

#### Example 21

Capsules, each dosed at 0.200 g and containing 20 mg of the active substance can be prepared.


Composition for 500 capsules:

4-(1-tetrahydropyrimidin-2-yl)-pyridine	10 g
Lactose	80 g
Corn starch	5 g
5 Magnesium stearate	5 g

This formulation is encapsulated in two-piece hard gelatin capsules and dosed at 0.200 g for each capsule.

CLAIMS

1. A bicyclic condensed pyrimidine compound having the following general formula (I)



wherein

- X is  $-\text{CH}_2-$ ,  $-\text{NH}-(\text{CH}_2)_n-$ ,  $-\text{O}-(\text{CH}_2)_n-$  or  $-\text{S}-(\text{CH}_2)_n-$  in which n is zero or 1;
- 10 A is a 4,5-fused imidazole ring N-substituted by  $\text{R}_3$  which is hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl or benzyl, or A is a 2,3-fused pyridine ring C-substituted by  $\text{R}_4$  which is hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl,  $\text{C}_1$ - $\text{C}_4$  alkoxy, halogen or  $\text{NR}_5\text{R}_6$  in which each of  $\text{R}_5$  and  $\text{R}_6$  independently is H or  $\text{C}_1$ - $\text{C}_4$  alkyl;
- 15 B is a bicyclic ring chosen from tetralin, indane and 2-oxindole;
- each of  $\text{R}_1$  and  $\text{R}_2$ , independently, is hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl, halogen, hydroxy,  $\text{C}_1$ - $\text{C}_4$  alkoxy,  $\text{C}_1$ - $\text{C}_4$  alkoxycarbonyl, nitro, cyano or  $\text{CF}_3$ ;
- 20 and the pharmaceutically acceptable salts thereof; and wherein, when at the same time, A is pyridine and B is a tetralin ring,  $\text{R}_4$  is H,  $\text{C}_1$ - $\text{C}_4$  alkyl,  $\text{C}_1$ - $\text{C}_4$  alkoxy or halogen and X is as defined above, then each of  $\text{R}_1$  and  $\text{R}_2$  is other than H; and wherein, when at the same time, A is imidazole, X
- 25 is  $-\text{NH}-(\text{CH}_2)_n-$  as defined above, and B is an indan ring unsubstituted or substituted by one or more of halogen, hydroxy,  $\text{C}_1$ - $\text{C}_4$  alkoxy and nitro, then  $\text{R}_3$  is other than  $\text{C}_1$ - $\text{C}_4$

alkyl or benzyl.

2. A compound of formula (I), according to claim 1, wherein X, A and B are as defined in claim 1, R<sub>1</sub> is hydrogen  
5 or halogen, R<sub>4</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkoxy, and R<sub>2</sub> and R<sub>3</sub> are H; and the pharmaceutically acceptable salts thereof.

3. A compound selected from:

- 4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;
- 10 7-methoxy-4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylmethlamino)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethlamino)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-yloxy)-pyrido[2,3-d]pyrimidine;
- 15 7-methoxy-4-(2-oxindol-5-yloxy)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;
- 20 4-(2-oxindol-5-ylmethythio)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethythio)-pyrido[2,3-d]pyrimidine;
- 4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;
- 25 4-(5-indanylamino)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(5-indanylamino)-pyrido[2,3-d]pyrimidine;
- 4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine;
- 4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;
- 30 7-methoxy-4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;
- 4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;
- 7-methoxy-4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;

- 4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;  
5 4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;  
N<sup>6</sup>-(1-tetralyl) adenine;  
N<sup>6</sup>-(3-bromo-1-tetralyl) adenine;  
N<sup>6</sup>-(5-indanyl) adenine;  
10 N<sup>6</sup>-(7-bromo-5-indanyl) adenine;  
N<sup>6</sup>-(2-oxindol-5-yl) adenine;  
N<sup>6</sup>-(1-tetralylmethyl) adenine;  
N<sup>6</sup>-(5-indanylmethyl) adenine;  
N<sup>6</sup>-(2-oxindol-5-ylmethyl) adenine;  
15 6-(1-tetralyloxy)-purine;  
6-(3-bromo-1-tetralyloxy)-purine;  
6-(5-indanyloxy)-purine;  
6-(7-bromo-5-indanyloxy)-purine;  
6-(2-oxindol-5-yloxy)-purine;  
20 6-(1-tetralylthio)-purine;  
6-(3-bromo-1-tetralylthio)-purine;  
6-(5-indanylthio)-purine;  
6-(7-bromo-5-indanylthio)-purine;  
6-(2-oxoindol-5-ylthio)-purine;  
25 6-(1-tetralylmethyl)-purine;  
6-(3-bromo-1-tetralylmethyl)-purine;  
6-(5-indanylmethyl)-purine;  
6-(7-bromo-5-indanylmethyl)-purine;  
6-(2-oxindol-5-ylmethyl)-purine;  
30 6-(1-tetralylmethoxy)-purine;  
6-(5-indanylmethoxy)-purine;




6-(2-oxindol-5-ylmethoxy)-purine;  
 6-(1-tetralylmethylthio)-purine;  
 6-(5-indanylmethylthio)-purine; and  
 6-(2-oxindol-5-ylmethylthio)-purine;

5 either as single isomers or as a mixture thereof or a pharmaceutically acceptable salt thereof.

4. A bicyclic condensed pyrimidine compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable  
 10 salt thereof, for use as an active therapeutic substance, in particular as tyrosine kinase inhibitor.

5. A pharmaceutical composition comprising a compound of formula (I), as defined in claim 1, or a pharmaceutically  
 15 salt thereof, as an active principle, and a pharmaceutically acceptable excipient.

6. A bicyclic condensed pyrimidine compound of formula (IA)



(IA)

20

wherein

X is  $-\text{CH}_2-$ ,  $-\text{NH}-(\text{CH}_2)_n-$ ,  $-\text{O}-(\text{CH}_2)_n-$  or  $-\text{S}-(\text{CH}_2)_n-$  in which n is zero or 1 ;

A is a 2,3-fused pyrimidine ring C-substituted by  $\text{R}_4$  which is  
 25 hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl,  $\text{C}_1$ - $\text{C}_4$  alkoxy, halogen or  $\text{NR}_5\text{R}_6$  in which each of  $\text{R}_5$  and  $\text{R}_6$  independently is H or  $\text{C}_1$ - $\text{C}_4$  alkyl;

B is a bicyclic ring chosen from tetralin, indane and 2-

oxindole;

each of R<sub>1</sub> and R<sub>2</sub>, independently, is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, halogen, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> alkoxycarbonyl, nitro, cyano or CF<sub>3</sub>;

- 5 or a pharmaceutically acceptable salts thereof for use as an active therapeutic substance, in particular as tyrosine kinase inhibitor.

7. A bicyclic condensed pyrimidine compound of formula  
10 (IA), for the use according to claim 6, which is selected from:

- 4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;  
4-(2-oxindol-5-ylmethyldamino)-pyrido[2,3-d]pyrimidine;  
15 7-methoxy-4-(2-oxindol-5-ylmethyldamino)-pyrido[2,3-d]pyrimidine;  
4-(2-oxindol-5-ylloxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(2-oxindol-5-ylloxy)-pyrido[2,3-d]pyrimidine;  
4-(2-oxindol-5-ylmethoxy) pyrido[2,3 d]pyrimidine;  
20 7-methoxy-4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;  
4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;  
4-(2-oxindol-5-ylmethythio)-pyrido[2,3-d]pyrimidine;  
7-methoxy 4-(2-oxindol-5-ylmethythio)-pyrido[2,3  
25 d]pyrimidine;  
4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;  
4-(5-indanyldamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanyldamino)-pyrido[2,3-d]pyrimidine;  
30 4-(5-indanylmethyldamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethyldamino)-pyrido[2,3-d]pyrimidine;


- 4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;  
5 4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;  
10 7-methoxy-4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralylamino)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylmethylamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralylmethylamino)-pyrido[2,3-d]pyrimidine;  
15 4-(1-tetralyloxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralyloxy)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylmethoxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralylmethoxy)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylthio)-pyrido[2,3-d]pyrimidine;  
20 7-methoxy-4-(1-tetralylthio)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylmethylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralylmethylthio)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylmethyl)-pyrido[2,3-d]pyrimidine; and  
7-methoxy-4-(1-tetralylmethyl)-pyrido[2,3-d]pyrimidine;  
25 either as single isomers or as a mixture thereof or a  
pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound of  
formula (IA), as defined in claim 6, as an active principle  
30 and a pharmaceutically acceptable excipient.

9. A compound selected from:

- 4-(1-tetralylamino)-pyrido[2,3-d]pyrimidine;  
 7-methoxy-4-(1-tetralylamino)-pyrido[2,3-d]pyrimidine;  
 4-(1-tetralylmethylamino)-pyrido[2,3-d]pyrimidine;  
 7-methoxy-4-(1-tetralylmethylamino)-pyrido[2,3-d]pyrimidine;  
 5 4-(1-tetralyloxy)-pyrido[2,3-d]pyrimidine;  
 7-methoxy-4-(1-tetralyloxy)-pyrido[2,3-d]pyrimidine;  
 4-(1-tetralylmethoxy)-pyrido[2,3-d]pyrimidine;  
 7-methoxy-4-(1-tetralylmethoxy)-pyrido[2,3-d]pyrimidine;  
 4-(1-tetralylthio)-pyrido[2,3-d]pyrimidine;  
 10 7-methoxy-4-(1-tetralylthio)-pyrido[2,3-d]pyrimidine;  
 4-(1-tetralylmethylthio)-pyrido[2,3-d]pyrimidine;  
 7-methoxy-4-(1-tetralylmethylthio)-pyrido[2,3-d]pyrimidine;  
 4-(1-tetralylmethyl)-pyrido[2,3-d]pyrimidine; and  
 7-methoxy-4-(1-tetralylmethyl)-pyrido[2,3-d]pyrimidine;  
 15 either as a single isomer or as a mixture thereof, or a  
 pharmaceutically acceptable salt thereof.

10. The use of a bicyclic condensed pyrimidine compound  
 of formula (IB)



(IB)

20

wherein

X is  $-\text{CH}_2-$ ,  $-\text{NH}-(\text{CH}_2)_n-$ ,  $-\text{O}-(\text{CH}_2)_n-$  or  $-\text{S}-(\text{CH}_2)_n-$  in which  
 n is zero or 1;

A is a 4,5-fused imidazole ring N-substituted by  $\text{R}_3$  which is  
 25 hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl or benzyl, or A is a 2,3-fused pyridine  
 ring C-substituted by  $\text{R}_4$  which is hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl,  $\text{C}_1$ - $\text{C}_4$   
 alkoxy, halogen or  $\text{NR}_5\text{R}_6$  in which each of  $\text{R}_5$  and  $\text{R}_6$

independently is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

B is a bicyclic ring chosen from tetralin, indane and 2-oxindole;

each of R<sub>1</sub> and R<sub>2</sub>, independently, is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, halogen, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> alkoxycarbonyl, nitro, cyano or CF<sub>3</sub>;

or a pharmaceutically acceptable salts thereof for use in the manufacture of a medicament having tyrosine kinase inhibiting activity.

10

11. The use of a bicyclic condensed pyrimidine compound of formula (IB), as defined in claim 10, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the control of immune system diseases, in inhibiting the development of the atheromatous plaque and restenosis, in the control of angiogenesis, as an anti-metastatic agent, in treating diabetic complications, in the treatment of pathological proliferative conditions, in treating tumors, including leukemia, and in the treatment of Alzheimer's disease.

20

12. The use according to claims 10 and 11, wherein the condensed pyrimidine compound is selected from:

4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;

25 7-methoxy-4-(2-oxindol-5-ylamino)-pyrido[2,3-d]pyrimidine;

4-(2-oxindol-5-ylmethyamino)-pyrido[2,3-d]pyrimidine;

7-methoxy-4-(2-oxindol-5-ylmethyamino)-pyrido[2,3-d]pyrimidine;

4-(2-oxindol-5-yloxy)-pyrido[2,3-d]pyrimidine;

30 7-methoxy-4-(2-oxindol-5-yloxy)-pyrido[2,3-d]pyrimidine;

4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;

7-methoxy-4-(2-oxindol-5-ylmethoxy)-pyrido[2,3-d]pyrimidine;

- 4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(2-oxindol-5-ylthio)-pyrido[2,3-d]pyrimidine;  
4-(2-oxindol-5-ylmethylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(2-oxindol-5-ylmethylthio)-pyrido[2,3-  
d]pyrimidine;  
4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(2-oxindol-5-ylmethyl)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylamino)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethylamino)-pyrido[2,3-d]pyrimidine;  
4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanyloxy)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethoxy)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylthio)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethylthio)-pyrido[2,3-d]pyrimidine;  
4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(5-indanylmethyl)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralylamino)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylmethylamino)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralylmethylamino)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralyloxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralyloxy)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralymethoxy)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralymethoxy)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylthio)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralylthio)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylmethylthio)-pyrido[2,3-d]pyrimidine;

- 7-methoxy-4-(1-tetralylmethylthio)-pyrido[2,3-d]pyrimidine;  
4-(1-tetralylmethyl)-pyrido[2,3-d]pyrimidine;  
7-methoxy-4-(1-tetralylmethyl)-pyrido[2,3-d]pyrimidine;  
N<sup>6</sup>-(1-tetralyl) adenine;  
5 N<sup>6</sup>-(3-bromo-1-tetralyl) adenine;  
N<sup>6</sup>-(5-indanyl) adenine;  
N<sup>6</sup>-(7-bromo-5-indanyl) adenine;  
N<sup>6</sup>-(2-oxindol-5-yl) adenine;  
N<sup>6</sup>-(1-tetralylmethyl) adenine;  
10 N<sup>6</sup>-(5-indanylmethyl) adenine;  
N<sup>6</sup>-(2-oxindol-5-ylmethyl) adenine;  
6-(1-tetralyloxy)-purine;  
6-(3-bromo-1-tetralyloxy)-purine;  
6-(5-indanyloxy)-purine;  
15 6-(7-bromo-5-indanyloxy)-purine;  
6-(2-oxindol-5-yloxy)-purine;  
6-(1-tetralylthio)-purine;  
6-(3-bromo-1-tetralylthio)-purine;  
6-(5-indanylthio)-purine;  
20 6-(7-bromo-5-indanylthio)-purine;  
6-(2-oxindol-5-ylthio)-purine;  
6-(1-tetralylmethyl)-purine;  
6-(3-bromo-1-tetralylmethyl)-purine;  
6-(5-indanylmethyl)-purine;  
25 6-(7-bromo-5-indanylmethyl)-purine;  
6-(2-oxindol-5-ylmethyl)-purine;  
6-(1-tetralylmethoxy)-purine;  
6-(5-indanylmethoxy)-purine;  
6-(2-oxindol-5-ylmethoxy)-purine;  
30 6-(1-tetralylmethylthio)-purine;  
6-(5-indanylmethylthio)-purine; and

6-(2-oxindol-5-ylmethylthio)-purine;  
either as single isomers or as a mixture thereof or a  
pharmaceutically acceptable salt thereof.


5 13. A method of treating a patient in need of a tyrosine  
kinase inhibitor, the method comprising administering to said  
patient a therapeutically effective amount of a compound of  
formula (IB), as defined in claim 10, or a pharmaceutically  
acceptable salt thereof.

10


14. Products containing a compound of formula (IB), as  
defined in claim 10, or a pharmaceutically acceptable salt  
thereof, and an additional antitumor agent as a combined  
preparation for simultaneous, separate or sequential use in  
15 anticancer therapy.

15. A process for the preparation of a bicyclic  
pyrimidine compound of formula (I), as defined in claim 1, or  
a pharmaceutically acceptable salt thereof, the process  
20 comprising:

a) reacting a compound of formula (II)



wherein A is as defined in claim 1 and L is a leaving group  
with an amine compound of formula (III)




25

wherein n, B, R<sub>1</sub> and R<sub>2</sub> are as defined in claim 1, thus  
obtaining a compound of formula (I) in which X is




NH (CH<sub>2</sub>)<sub>n</sub> ; or

b) reacting a compound of formula (II) as defined above, with an hydroxy compound of formula (IV)




5 wherein n, B, R<sub>1</sub> and R<sub>2</sub> are as defined in claim 1, thus obtaining a compound of formula (I) in which X is -O-(CH<sub>2</sub>)<sub>n</sub>-; or

c) reacting a compound of formula (II) as defined above, with a thio compound of formula (V)




10

wherein n, B, R<sub>1</sub> and R<sub>2</sub> are as defined in claim 1, thus giving a compound of formula (I) in which X is -S-(CH<sub>2</sub>)<sub>n</sub>-; or  
d) reacting a compound of formula (VI)



15 wherein B, R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are as defined in claim 1, with formamide (HCONH<sub>2</sub>), thus providing a compound of formula (I) wherein X is -CH<sub>2</sub>- and A is a 4,5-fused imidazole ring, or  
e) hydrolyzing and decarboxylating a compound of formula (VII)



wherein B, R<sub>1</sub>, R<sub>2</sub> and R<sub>4</sub> are as defined in claim 1, thus providing a compound of formula (I), wherein X is -CH<sub>2</sub>- and A is a 2,3- fused pyridine ring;

- 5 and, if desired, converting a compound of formula (I) into another compound of formula (I), and/or, if desired, converting a compound of formula (I) into a salt thereof, and/or, if desired, converting a salt of a compound of formula (I) into a free compound of formula (I), and/or, if
- 10 desired, separating a mixture of isomers of a compound of formula (I) into the single isomers.

## INTERNATIONAL SEARCH REPORT

Intern. Application No.

PCT/EP 96/04450

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D473/34 C07D473/30 C07D473/38 C07D473/00 C07D471/04  
A61K31/52

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Maximum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than maximum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 212 535 (BOEHRINGER MANNHEIM GMBH) 4 March 1987 see page 1 - page 7; claims ---	1-15
A	US,A,4 751 292 (JUAN E. FOX) 14 June 1988 see column 8 - column 10; claims ---	1-15
A	GB,A,828 522 (J.R.GEIGY A.) 17 February 1960 see the whole document ---	1-15
A	WO,A,93 11106 (PFIZER INC.) 10 June 1993 see page 19, line 20-25 see page 48 - page 61; claims ---	1-15
A	US,A,3 112 192 (EDMUND F. FEICHTMEIR ET AL) 26 November 1963 see the whole document ---	1-15
-/--		

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier document but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
 "&" document member of the same patent family

Date of the actual completion of the international search

16 January 1997

Date of mailing of the international search report

22.01.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2240, Tx 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

Luyten, H

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/04460

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO, A, 96 06845 (DISCOVERY THERAPEUTICS INC.) 7 March 1996 see page 29 - page 36; claims ---	1-15
A	EP, A, 0 414 386 (ELI LILLY AND COMPANY) 27 February 1991 cited in the application see page 42 - page 51; claims -----	1-15

# INTERNATIONAL SEARCH REPORT

national application No.

PCT/EP 96/04460

## Box I (Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet))

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 13 is directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 5.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

information on patent family members

Inter. Application No

PCT/EP 96/84460

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-212535	04-03-87	DE-A- 3529497	26-02-87
		JP-B- 6092407	16-11-94
		JP-A- 62045588	27-02-87
		US-A- 4853386	01-08-89
US-A-4751292	14-06-88	NONE	
GB-A-828522		NONE	
WO-A-9311106	10-06-93	AU-B- 671959	19-09-96
		AU-A- 2896192	28-06-93
		BR-A- 9206810	31-10-95
		CA-A- 2124206	10-06-93
		CZ-A- 9401280	15-02-95
		EP-A- 0619805	19-10-94
		FI-A- 942395	24-05-94
		HU-A- 69705	28-09-95
		JP-A- 8239363	17-09-96
		JP-T- 6510793	01-12-94
		NO-A- 941918	24-05-94
		NZ-A- 245243	21-12-95
		PT-A- 101067	30-06-94
		ZA-A- 9209082	24-05-94
US-A-3112192	26-11-63	NONE	
WO-A-9606845	07-03-96	AU-A- 3370695	22-03-96
EP-A-414386	27-02-91	US-A- 5034393	23-07-91
		AU-B- 634562	25-02-93
		AU-A- 5982690	31-01-91
		CA-A- 2021925	28-01-91
		JP-A- 3066689	22-03-91
		US-A- 5350749	27-09-94